Fluvastatin potassium | CAS#1009811-63-5 | hypercholesterolemia

MedKoo Cat#: 413340 | Name: Fluvastatin potassium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

Chemical Structure

Fluvastatin potassium

CAS#1009811-63-5 (potassium)

Theoretical Analysis

MedKoo Cat#: 413340

Name: Fluvastatin potassium

CAS#: 1009811-63-5 (potassium)

Chemical Formula: C24H25FKNO4

Exact Mass:

Molecular Weight: 449.56

Elemental Analysis: C, 64.12; H, 5.61; F, 4.23; K, 8.70; N, 3.12; O, 14.24

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

93957-55-2 (sodium) 94061-81-1 (sodium) 93957-54-1 (free acid) 500103-16-2 (calcium) 1009811-63-5 (potassium)

Synonym

Fluvastatin; XU62320; XU-62320; XU 62320; Fluvastatin sodium;

IUPAC/Chemical Name

potassium (3S,5R,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate

InChi Key

WHNIQJXBZHLZFN-RPQBTBOMSA-M

InChi Code

InChI=1S/C24H26FNO4.K/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1

SMILES Code

O=C([O-])C[C@@H](O)C[C@@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3.[K+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM.

In vitro activity:

Fluvastatin significantly restored H2O2-induced neuronal death in a dose-dependent manner (P < 0.05) and reversed H2O2-induced oxidative stress and damage via restoring mitochondrial function in neuronal cells (P < 0.05). Reference: J Pharm Pharmacol. 2021 Mar 8;73(4):515-521. https://pubmed.ncbi.nlm.nih.gov/33793833/

In vivo activity:

Fluvastatin preconditioning in rats improved left ventricular dysfunction, reduced HMGB1/TLR4/NF-κB expressions, and inhibited cardiomyocyte apoptosis, autophagy, and inflammation reaction. Moreover, treatment with fluvastatin ameliorated myocardial injury by reducing infarct size, causing less damage to cardiac structure, downregulating autophagy-related protein expression and releasing pro-inflammation mediators. Reference: Mol Biol Rep. 2021 May;48(5):3893-3901. https://pubmed.ncbi.nlm.nih.gov/34032975/

	Solvent	mg/mL	mM
Solubility
	DMSO	14.0	34.02
	DMF	20.0	48.61
	DMF:PBS (pH 7.2) (1:1)	0.5	1.22
	Ethanol	1.0	2.43

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 449.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wang M, Wang J, Liu M, Chen G. Fluvastatin protects neuronal cells from hydrogen peroxide-induced toxicity with decreasing oxidative damage and increasing PI3K/Akt/mTOR signalling. J Pharm Pharmacol. 2021 Mar 8;73(4):515-521. doi: 10.1093/jpp/rgaa058. PMID: 33793833. 2. Zhao K, Tian Y, Wang J, Chen C, Pan B, Yan Z, Zhu S, Xu K. Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2. Biomed Res Int. 2020 Dec 19;2020:7619849. doi: 10.1155/2020/7619849. PMID: 33415155; PMCID: PMC7769635. 3. Ding HS, Yang J, Yang J, Guo X, Tang YH, Huang Y, Chen Z, Fan ZX, Huang CX. Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Mol Biol Rep. 2021 May;48(5):3893-3901. doi: 10.1007/s11033-021-06326-9. Epub 2021 May 25. PMID: 34032975. 4. Yu JS, Shin DH, Kim JS. Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome. Pharmaceutics. 2020 Nov 24;12(12):1133. doi: 10.3390/pharmaceutics12121133. PMID: 33255298; PMCID: PMC7760927.

In vitro protocol:

In vivo protocol:

1. Ding HS, Yang J, Yang J, Guo X, Tang YH, Huang Y, Chen Z, Fan ZX, Huang CX. Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway. Mol Biol Rep. 2021 May;48(5):3893-3901. doi: 10.1007/s11033-021-06326-9. Epub 2021 May 25. PMID: 34032975. 2. Yu JS, Shin DH, Kim JS. Repurposing of Fluvastatin as an Anticancer Agent against Breast Cancer Stem Cells via Encapsulation in a Hyaluronan-Conjugated Liposome. Pharmaceutics. 2020 Nov 24;12(12):1133. doi: 10.3390/pharmaceutics12121133. PMID: 33255298; PMCID: PMC7760927.

1: Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for lowering lipids. Cochrane Database Syst Rev. 2018 Mar 6;3(3):CD012282. doi: 10.1002/14651858.CD012282.pub2. PMID: 29508377; PMCID: PMC6494196. 2: Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvärinen M, Tapaninen T, Backman JT, Niemi M. Enantiospecific Pharmacogenomics of Fluvastatin. Clin Pharmacol Ther. 2019 Sep;106(3):668-680. doi: 10.1002/cpt.1463. Epub 2019 May 14. PMID: 30989645; PMCID: PMC6767327. 3: Okubo K, Isono M, Miyai K, Asano T, Sato A. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells. Cancer Sci. 2020 Jan;111(1):112-126. doi: 10.1111/cas.14225. Epub 2019 Nov 25. PMID: 31675763; PMCID: PMC6942444. 4: Lawrence JM, Reckless JP. Fluvastatin. Expert Opin Pharmacother. 2002 Nov;3(11):1631-41. doi: 10.1517/14656566.3.11.1631. PMID: 12437496. 5: Hayashi K, Nakazato Y, Morito N, Sagi M, Fujita T, Anzai N, Chida M. Fluvastatin is effective against thymic carcinoma. Life Sci. 2020 Jan 1;240:117110. doi: 10.1016/j.lfs.2019.117110. Epub 2019 Nov 28. PMID: 31786191. 6: Paez PA, Kolawole M, Taruselli MT, Ajith S, Dailey JM, Kee SA, Haque TT, Barnstein BO, McLeod JJA, Caslin HL, Kiwanuka KN, Fukuoka Y, Le QT, Schwartz LB, Straus DB, Gewirtz DA, Martin RK, Ryan JJ. Fluvastatin Induces Apoptosis in Primary and Transformed Mast Cells. J Pharmacol Exp Ther. 2020 Jul;374(1):104-112. doi: 10.1124/jpet.119.264234. Epub 2020 May 20. PMID: 32434944; PMCID: PMC7306917. 7: Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen- Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2024-31. doi: 10.1016/S0140-6736(03)13638-0. PMID: 12814712. 8: Zhang T, Bai R, Wang Q, Wang K, Li X, Liu K, Ryu J, Wang T, Chang X, Ma W, Bode AM, Xia Q, Song Y, Dong Z. Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis. Cancer Prev Res (Phila). 2019 Dec;12(12):837-848. doi: 10.1158/1940-6207.CAPR-19-0211. Epub 2019 Sep 25. PMID: 31554629. 9: Nishiya M, Yasuhira S, Shibazaki M, Oikawa H, Masuda T, Maesawa C. Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells. Anticancer Drugs. 2019 Jun;30(5):451-457. doi: 10.1097/CAD.0000000000000757. PMID: 30920401. 10: Yin N, Zhang H, Ye R, Dong M, Lin J, Zhou H, Huang Y, Chen L, Jiang X, Nagaoka K, Zhang C, Jin W. Fluvastatin Sodium Ameliorates Obesity through Brown Fat Activation. Int J Mol Sci. 2019 Apr 1;20(7):1622. doi: 10.3390/ijms20071622. PMID: 30939798; PMCID: PMC6479292.